Symbol="ASLN"
AssetType="Common Stock"
Name="Aslan Pharmaceuticals Ltd ADR"
Description="ASLAN Pharmaceuticals Limited, a biopharmaceutical company focused on clinical phase immunology, is dedicated to developing various treatments to transform the lives of patients. The company is headquartered in Singapore."
CIK="1722926"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="83 CLEMENCEAU AVENUE, #12-03 UE SQUARE, SINGAPORE, SG"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="35012200"
EBITDA="-44130628"
PERatio="None"
PEGRatio="None"
BookValue="0.382"
DividendPerShare="0"
DividendYield="0"
EPS="-3"
RevenuePerShareTTM="0.811"
ProfitMargin="0"
OperatingMarginTTM="-3.68"
ReturnOnAssetsTTM="-0.406"
ReturnOnEquityTTM="-2.377"
RevenueTTM="12000000"
GrossProfitTTM="79821000"
DilutedEPSTTM="-3"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="15.67"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="19.05"
PriceToBookRatio="1.584"
EVToRevenue="16.94"
EVToEBITDA="-0.062"
Beta="1.748"
num_52WeekHigh="4.69"
num_52WeekLow="1.702"
num_50DayMovingAverage="2.633"
num_200DayMovingAverage="3.169"
SharesOutstanding="16672500"
DividendDate="None"
ExDividendDate="None"
symbol="ASLN"
open="2.14"
high="2.16"
low="2.10"
price="2.12"
volume="6650.00"
latest_trading_day="2023-08-31"
previous_close="2.10"
change="0.03"
change_percent="1.1905%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="58"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="42"
Volume_recent_avg="104605"
Change_recent_avg="0.01"
Delta_recent_avg="0.23"
Variance_recent_avg="0.12"
Change_ratio_recent_avg="-0.03"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="42"
Aroon_momentum_negative="58"
image_negative_thumbnail_id_1="175"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0001.jpeg"
image_negative_thumbnail_id_2="1103"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0136.jpeg"
image_neutral_thumbnail_id_1="597"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0002.jpeg"
image_neutral_thumbnail_id_2="549"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0050.jpeg"
image_positive_thumbnail_id_1="990"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0152.jpeg"
image_positive_thumbnail_id_2="969"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0131.jpeg"
image_professor_thumbnail_id_1="1180"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0014.jpeg"
image_professor_thumbnail_id_2="1196"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0030.jpeg"
